Theresa Matkovits, Ph.D., brings over 20+ years global drug development, commercialization, and leadership experience to ContraVir. A seasoned and established leader in the Pharmaceutical and Biotech Sectors, Dr. Matkovits has led Global Drug Development Teams bringing to market a number of approved medicines to several global markets.

Dr. Matkovits earned her Ph.D. in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of NJ. Dr. Matkovits started her career at the Roche Institute of Molecular Biology and Organon where she held positions in clinical development in the Women’s Health area. In 1997, Dr. Matkovits joined Novartis in Global Drug Development, taking on leadership roles in the clinical development for the marketed antipsychotic, Fanapt. Dr. Matkovits advanced her career in Novartis, taking on Global Drug Development leadership for the CNS Psychiatry Portfolio including Schizophrenia, Anxiety Disorders, and Depression. She served as Global Program Leader for a number of early-phase, mid-phase, and late-phase development compounds and in-line brands such as Clozaril. In 2010, Dr. Matkovits transitioned to the US commercial organization in Novartis where she lead the Strategic Planning and Operations Group for the General Medicines Portfolio in Medical Affairs. Dr, Matkovits was responsible for the oversight and leadership of Continuing Medical Education, Resource and Strategic Planning, Organizational Development and Training, Compliance, Project Management, IT for the Field Medical Team, and the establishment of a REMs Center of Excellence.

Dr. Matkovits subsequently joined The Medicines Company in 2010 as Vice President, Innovation Leader, where she was recruited and lead the successful global development and registration of oritavancin, which is now approved and commercialized in the US and EU as ORBACTIV. In 2013, Dr. Matkovits joined NPS Pharmaceuticals as a consultant to the CEO to lead the integration of two commercial assets acquired from Takeda into NPS. Dr. Matkovits played a critical role in driving the expansion of NPS from a US-centric to a global development and commercial organization. In 2012, Dr. Matkovits joined NPS as Global Program Leader to lead the registration of Natpara for the US and EU Markets. Under her leadership, the team had a positive vote in front of an FDA Advisory Committee and the approval was secured for the US for Natpara for the treatment of hypoparathyroidism in January 2015. Dr. Matkovits was accepted into Women in Bio’s inaugural Boardroom Ready Class of 2016.